Skip header information|
Wadsworth Center Home - Science in the Pursuit of Health|
Main Body

Investigators and Program Directors

Erasmus Schneider

Erasmus Schneider

Research Scientist, Wadsworth Center, Molecular Diagnostics
Associate Professor, School of Public Health, Biomedical Sciences

Ph.D., University of Bern, Switzerland
Postdoctoral training, University of Auckland, Johns Hopkins University Medical School, National Cancer Institute

E-mail: schneid@wadsworth.org.

<< Research Interests

Select Publications

  • Marshall LA, Rhee MS, Hofmann L, Khodjakov A, Schneider, E. (2005) Increased lysosomal uptake of methotrexate-polyglutamates in two methotrexate-resistant cell lines with distinct mechanisms of resistance. Biochem Pharmacol. 71; 203-213. PubMed
  • Rhee, M.S. and Schneider, E. (2005) Lack of an effect of breast cancer resistance protein (BCRP/ABCG2) overexpression on methotrexate polyglutamate export and folate accumulation in a human breast cancer cell line. Biochem. Pharmacol. 69; 123-132. PubMed
  • Kowalski, P., Farley. K.M., Lage, H. and Schneider, E. (2004) Effective knock down of very high ABCG2 expression by a hammerhead ribozyme. Anticancer Res. 24; 2231-2235. PubMed
  • Volk, E.L. and Schneider, E. (2003) Wild-type Breast Cancer Resistance Protein (BCRP) is a Methotrexate Polyglutamate Transporter. Cancer Res. 63; 5538-5543. PubMed
  • Volk, E.L., Farley, K.M., Wu, Y., Li, F., Robey, R.W., and Schneider, E. (2002) Overexpression of wild-type Breast Cancer Resistance Protein mediates methotrexate resistance. Cancer Res. 62; 5035-5040. PubMed
  • Rocchi, E., Khodjakov, A., Volk, E.L., Yang, C.-H.J., Litman, T., and Schneider, E. (2000) The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochim. Biophys. Res. Commun. 271, 42-46. PubMed
  • Volk, E.L., Rohde, K., Rhee, M., McGuire, J.J., Doyle, L.A., Ross, D.D., and Schneider, E. (2000) Methotrexate cross-resistance in a mitoxantrone selected multidrug-resistant MCF7 breast cancer cell line is due to enhanced energy-dependent drug efflux. Cancer Res. 60; 3514-3521. PubMed
  • Yang C.-H., Schneider E., Kuo M.-L., Volk, E.L., Rocchi, E. and Chen, Y.-C. (2000) BCRP/MXR/ABCP Expression in Topotecan-Resistant Human Breast Carcinoma Cells, Biochem. Pharm. 60; 831-837. PubMed

Contact Information

E-mail: schneid@wadsworth.org.